Ascendis Pharma weakness follows death reported in FAERS, says BofA

BofA notes that Ascendis Pharma (ASND) shares are under pressure following a death reported in the FAERS database for Yorvipath, though the analyst also notes that company management express confidence that the event is unrelated to Yorvipath and cites other comorbidities as the likely cause. The firm, which awaits more details but remains confident in the risk/benefit of Yorvipath, has a Buy rating and $242 price target on Ascendis shares.